The development of cardiomyopathy in HCV-infected patients, due to the above-mentioned evidence, may inevitably lead to a diagnosis of HCV-related cardiomyopathy, whereas none of the above mentioned articles have discussed a history of IFN therapy. Here, IFNA1 is linked to cardiomyopathy.